Table 1.
Clinical characteristics of the study population at enrollment.
| Variables | Sarcoidosis Patients with PE (n = 15) |
Sarcoidosis Patients without PE (n = 241) |
p-Value |
|---|---|---|---|
| Clinical Characteristics | |||
| Gender (n, %) Male; Female | M: 4 (27%); F: 11 (73%) | M: 80 (33%) F: 161 (67%) | p > 0.05 |
| Age at diagnosis (mean ± SD) | 50 ± 11 | 47 ± 13 | p > 0.05 |
| Age at enrollment (mean ± SD) | 55 ± 12 | 54 ± 13 | p > 0.05 |
| Current smoker (n, %) | 1 (7%) | 14 (6%) | p > 0.05 |
| Former smoker (n, %) | 2 (13%) | 35 (14%) | p > 0.05 |
| Obesity, BMI > 30 (n, %) | 2 (13%) | 27 (11%) | p > 0.05 |
| Previous episodes of venous thromboembolism (n, %) | 3 (20%) | 8 (3%) | p = 0.020 |
| Cardiac comorbidities (n, %) | 2 (13%) | 27 (11%) | p > 0.05 |
| Immunological disorders (n, %) | 2 (13%) | 19 (9%) | p > 0.05 |
| History of cancers (n, %) | 1 (7%) | 7 (3%) | p > 0.05 |
| Treatment Regimens | |||
| Corticosteroids (n, %) | 11 (73%) | 190 (78%) | p > 0.05 |
| Methotrexate (n, %) | 7 (46%) | 107 (44%) | p > 0.05 |
| Hydroxychloroquine (n, %) | 6 (40%) | 80 (34%) | p > 0.05 |
| Biological drugs (n, %) | 1 (7%) | 8 (3%) | p > 0.05 |
| Pentoxifylline (n, %) | 2 (13%) | 34 (14%) | p > 0.05 |
| Mycophenolate mofetil (n, %) | 0 (0%) | 3 (1%) | p > 0.05 |
| Azathioprine (n, %) | 1 (7%) | 11 (5%) | p > 0.05 |
Legend: BMI = body mass index, n = number of patients, % = percentage of patients.